Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

• Initial Visit:

• study inclusion criteria reviewed
• consent forms reviewed
• creation of facial map for actinic keratoses
• face cleansed with chlorhexidine soap
• light curettage of precancerous skin lesions
• application of topical aminolevulinic acid (ALA)
• application of sunscreen
• patient then spends 2 hours outdoors in a shaded area
• after treatment the patient is to remain indoors for 48 hours
• 3 month follow up visit

• facial map of actinic keratoses used to document treatment response
• 6 month follow up visit

• facial map of actinic keratoses used to document treatment response

Inclusion criteria

• Clinical diagnosis of >10 actinic keratoses on head and neck
• Age ≥ 18 years (Because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients <18 years of age, children are excluded from this study)
• Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

• Patients currently undergoing anti-neoplastic therapy including but not limited to the following:

• Topical imiquimod
• Topical 5-fluorouracil
• Topical ingenol mebutate
• Topical diclofenac
• Topical retinoids
• Oral acitretin
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid
• Patients with a known photosensitivity disorder including but not limited to porphyria, lupus, polymorphous light eruption, or immunobullous disease.
• Patients taking known photosensitizing medications including but not limited to griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines.
• pregnancy